CognitiveResearch Phase

P21 (Peptide)

Subcutaneous injection, Intranasal

Overview

A small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neurogenesis and synaptic plasticity. P21 is a tetrapeptide that crosses the blood-brain barrier and enhances dentate gyrus neurogenesis by increasing BDNF expression.

Mechanism of Action

Unlike full-length CNTF, P21 does not activate the JAK-STAT pathway or produce the anorectic and immunogenic effects of the parent protein..

Research Summary & Key Findings

Preclinical studies in Alzheimer's disease mouse models showed significant improvements in spatial learning and memory, correlated with increased hippocampal neurogenesis and synaptic density (Bolognin et al., Neurobiol Dis, 2014). Reduced tau hyperphosphorylation and neurofibrillary pathology in transgenic mice. Currently in preclinical development with no human clinical trials completed.

Clinical Status

Research Phase

P21 (Peptide) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionIntranasal

Related Peptides in Cognitive

Find a Provider

Find a verified provider who offers P21 (Peptide) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply P21 (Peptide).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.